India, June 22 -- Now that Definium Therapeutics Inc. (DFTX) has reported positive results from its Phase 3 Emerge trial, greater clarity has emerged around the clinical profile and potential of its lead investigational asset, DT120 Orally Disintegrating Tablet.
Emerge is the company's first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 mcg in adults with major depressive disorder (MDD).
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....